Provided by Tiger Trade Technology Pte. Ltd.

ARCELLX, INC.

68.50
-0.1500-0.22%
Post-market: 68.500.00000.00%17:23 EST
Volume:696.39K
Turnover:48.08M
Market Cap:3.96B
PE:-17.41
High:70.55
Open:69.24
Low:68.23
Close:68.65
52wk High:94.07
52wk Low:47.86
Shares:57.82M
Float Shares:39.70M
Volume Ratio:1.02
T/O Rate:1.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9351
EPS(LYR):-2.0040
ROE:-47.18%
ROA:-21.34%
PB:8.99
PE(LYR):-34.18

Loading ...

Rothschild & Co Redburn Downgrades Arcellx to Neutral From Buy, Adjusts PT to $82 From $113

MT Newswires Live
·
Feb 12

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcellx Inc (ACLX), Align Tech (ALGN) and M3 (OtherMTHRF)

TIPRANKS
·
Feb 05

Arcellx Price Target Maintained With a $115.00/Share by HC Wainwright & Co.

Dow Jones
·
Feb 05

Arcellx stellt neue Daten zur Sicherheit und Wirksamkeit von Anito-cel auf Fachkongress vor

Reuters
·
Feb 04

Arcellx Unveils Data Showing Anito-cel’s D-Domain Binder Achieves High Target Specificity in Multiple Myeloma

Reuters
·
Feb 04

Analysts Offer Insights on Healthcare Companies: Steris (STE), Arcellx Inc (ACLX) and BioCryst (BCRX)

TIPRANKS
·
Jan 30

Arcellx Showcases CAR T Advances and Access Solutions for Multiple Myeloma at Tandem Meetings

Reuters
·
Jan 22

Arcellx Unveils New Data Highlighting Anito-cel's Efficacy and Market Impact in Multiple Myeloma

Reuters
·
Jan 22

Canaccord Genuity Keeps Their Buy Rating on Arcellx Inc (ACLX)

TIPRANKS
·
Jan 21

Arcellx Director David Charles Lubner Reports Disposal of Common Shares

Reuters
·
Jan 21

Citi Reaffirms Their Buy Rating on Arcellx Inc (ACLX)

TIPRANKS
·
Jan 13

Arcellx Coverage Assumed by UBS at Buy

Dow Jones
·
Jan 08

A Look At Arcellx (ACLX) Valuation After New US$209.2 Million Shelf Registration Filing

Simply Wall St.
·
Jan 06

Reassessing Arcellx (ACLX) Valuation After Wells Fargo’s Positive CAR‑T Coverage Launch

Simply Wall St.
·
Dec 25, 2025

Innovative Drug Sector Boost! Wells Fargo Bets on Arcellx (ACLX.US) to Reshape Myeloma Treatment Landscape, Predicts Over 50% Stock Surge

Stock News
·
Dec 23, 2025

Is Wells Fargo’s Anito-cel Endorsement Reframing the Investment Case for Arcellx (ACLX)?

Simply Wall St.
·
Dec 23, 2025

What Arcellx (ACLX)'s Anito‑cel Phase 2 Data Means For Shareholders

Simply Wall St.
·
Dec 11, 2025

Cancer Study Buoys These Small Biotechs -- Barrons.com

Dow Jones
·
Dec 10, 2025

Arcellx (ACLX) Valuation Check After Strong Phase 2 iMMagine-1 Results for Anito-cel in Multiple Myeloma

Simply Wall St.
·
Dec 09, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Five Below, Boeing, Instacart

Reuters
·
Dec 09, 2025